Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506.
Takaya
S
S
Pittsburgh Transplant Institute, Pennsylvania.
Bronsther
O
O
Abu-Elmagd
K
K
Ramos
H
H
Fung
J J
JJ
Todo
S
S
Starzl
T E
TE
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000527:Alprostadil / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D015994:Incidence; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D016559:Tacrolimus / Q000097:blood / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D003404:Creatinine; D000527:Alprostadil; D016559:Tacrolimus